Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone
Citations Over TimeTop 14% of 2017 papers
Abstract
Objective To determine the prognostic utility of serum pre-albumin in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (AA). Patients and Methods 112 chemotherapy pretreated or chemotherapy-naive patients were scheduled for systemic treatment with AA. Serum pre-albumin levels were measured before and after 3 months of AA treatment. Univariate and multivariate analyses were performed to determine prognostic factors that were associated with PSA progression-free survival (PSA-PFS), radiographic PFS (rPFS) and overall survival (OS). The Harrell concordance index with variables only or combined pre-albumin data were used to evaluate the prognostic accuracy. Results The group of patients with baseline pre-albumin value ≥20mg/dL had a longer OS, PSA-PFS, rPFS than those with pre-albumin value Conclusion Low pretreatment serum pre-albumin is a negative independent prognosticator of survival outcomes in mCRPC treated with AA and also increases the accuracy of established prognostic model. Serial pre-albumin evaluation might help clinicians guide clinical treatment of mCRPC patients.
Related Papers
- → Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer(2020)71 cited
- → Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer(2019)21 cited
- → Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer(2016)7 cited
- → Albumin survival in patients with massive small-bowel resection(1967)1 cited
- Changes in the level of C-reactive protein and albumin in non-Hodgkin lymphoma patients with chemotherapy(2015)